Literature DB >> 17119990

Preliminary multi-institutional prospective pathologic and molecular studies support preservation of sublevel IIB and level IV for laryngeal squamous carcinoma with clinically negative neck.

Alfio Ferlito1, Carl E Silver, Carlos Suárez, Alessandra Rinaldo.   

Abstract

Level II-IV selective neck dissection, often performed bilaterally, has become the procedure of choice for elective dissection of the clinically negative (N0) neck in the treatment of laryngeal cancer. The most significant morbidity of this procedure is dysfunction of the accessory nerve, incurred by the necessity of mobilization and retraction of the nerve in order to remove the contents of sublevel IIB. Other morbidity includes possible injury to the phrenic nerve and chylous fistula. These complications are associated with the dissection of level IV. A number of prospective multi-institutional studies of the distribution of cervical lymph node metastases in the neck indicate that lymph nodes in sublevel IIB and level IV are rarely involved in cases of laryngeal cancer with N0 neck. Information was obtained by the study of neck dissection specimens by conventional light microscopy, and by molecular analysis of the specimens. Molecular analysis reveals a significant number of metastases that are not discovered by light microscopy, and is thus essential for this type of evaluation. The authors conclude that these preliminary studies indicate that it is safe and appropriate to eliminate dissection of sublevel IIB and level IV from the elective neck dissection performed for laryngeal cancer with N0 neck. This practice will reduce both operating time and morbidity, particularly accessory nerve dysfunction, without compromising the oncologic result. Further prospective studies are needed to confirm these conclusions.

Entities:  

Mesh:

Year:  2006        PMID: 17119990     DOI: 10.1007/s00405-006-0209-5

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  21 in total

1.  Lymphatic metastasis to the supraretrospinal recess in laryngeal squamous cell carcinoma.

Authors:  Ahmet Koybasioğlu; Sabri Uslu; Metin Yilmaz; Erdoğan Inal; Fikret Ileri; Korhan Asal
Journal:  Ann Otol Rhinol Laryngol       Date:  2002-01       Impact factor: 1.547

2.  Neck dissection classification update: revisions proposed by the American Head and Neck Society and the American Academy of Otolaryngology-Head and Neck Surgery.

Authors:  K Thomas Robbins; Garry Clayman; Paul A Levine; Jesus Medina; Roy Sessions; Ashok Shaha; Peter Som; Gregory T Wolf
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2002-07

3.  Clinical value of genetically diagnosed lymph node micrometastasis for patients with oral squamous cell carcinoma.

Authors:  Yutaka Yamazaki; Itsuo Chiba; Atsuko Hirai; Chiharu Satoh; Noriyuki Sakakibara; Ken-ichi Notani; Tadashi Iizuka; Yasunori Totsuka
Journal:  Head Neck       Date:  2005-08       Impact factor: 3.147

4.  Do pathologic and molecular analyses of neck dissection specimens justify the preservation of level IV for laryngeal squamous carcinoma with clinically negative neck?

Authors:  Mohamed N Elsheikh; Alfio Ferlito; Alessandra Rinaldo; Ashok R Shaha; Avi Khafif; H Hakan Coskun; Luiz P Kowalski; Jesus E Medina
Journal:  J Am Coll Surg       Date:  2005-11-21       Impact factor: 6.113

Review 5.  Prospective studies of neck dissection specimens support preservation of sublevel IIB for laryngeal squamous carcinoma with clinically negative neck.

Authors:  Alessandra Rinaldo; Mohamed N Elsheikh; Alfio Ferlito; Carlos T Chone; Hakan H Coskun; Ahmet Köybasiŏglu; Ramon M Esclamado; Toby H Corlette; Yoav P Talmi
Journal:  J Am Coll Surg       Date:  2006-06       Impact factor: 6.113

Review 6.  Importance of molecular analysis in detecting cervical lymph node metastasis in head and neck squamous cell carcinoma.

Authors:  Mohamed N Elsheikh; Alessandra Rinaldo; Hiroyuki Hamakawa; Magdy E Mahfouz; Juan Pablo Rodrigo; Joseph Brennan; Kenneth O Devaney; Jennifer R Grandis; Alfio Ferlito
Journal:  Head Neck       Date:  2006-09       Impact factor: 3.147

7.  Pain, quality of life, and spinal accessory nerve status after neck dissection.

Authors:  J E Terrell; D E Welsh; C R Bradford; D B Chepeha; R M Esclamado; N D Hogikyan; G T Wolf
Journal:  Laryngoscope       Date:  2000-04       Impact factor: 3.325

8.  Quantitative molecular detection of minimal residual head and neck cancer in lymph node aspirates.

Authors:  Eline J C Nieuwenhuis; Lies H Jaspars; Jonas A Castelijns; Branco Bakker; Richard G A Wishaupt; Fedor Denkers; C René Leemans; Gordon B Snow; Ruud H Brakenhoff
Journal:  Clin Cancer Res       Date:  2003-02       Impact factor: 12.531

9.  The impact of neck dissection on health-related quality of life.

Authors:  Sean Laverick; Derek Lowe; James S Brown; E David Vaughan; Simon N Rogers
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2004-02

10.  Molecular assessment of neck dissections supports preserving level IIB lymph nodes in selective neck dissection for laryngeal squamous cell carcinoma with a clinically negative neck.

Authors:  Mohamed Nasser Elsheikh; Magdy Elsayed Mahfouz; Elsayed I Salim; Ehab A Elsheikh
Journal:  ORL J Otorhinolaryngol Relat Spec       Date:  2006-02-07       Impact factor: 1.538

View more
  10 in total

Review 1.  Neck dissection: present and future?

Authors:  Alfio Ferlito; Carl E Silver; Alessandra Rinaldo
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-06       Impact factor: 2.503

2.  Level IIb lymph node metastasis in thyroid papillary carcinoma.

Authors:  Yusuf Vayisoglu; Cengiz Ozcan; Ozgur Turkmenoglu; Kemal Gorur; Murat Unal; Ahmet Dag; Koray Ocal
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-01-07       Impact factor: 2.503

Review 3.  The evolving role of selective neck dissection for head and neck squamous cell carcinoma.

Authors:  K Thomas Robbins; Alfio Ferlito; Jatin P Shah; Marc Hamoir; Robert P Takes; Primož Strojan; Avi Khafif; Carl E Silver; Alessandra Rinaldo; Jesus E Medina
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-08-19       Impact factor: 2.503

Review 4.  Contemporary management of cancer of the oral cavity.

Authors:  Eric M Genden; Alfio Ferlito; Carl E Silver; Robert P Takes; Carlos Suárez; Randall P Owen; Missak Haigentz; Sandro J Stoeckli; Ashok R Shaha; Alexander D Rapidis; Juan Pablo Rodrigo; Alessandra Rinaldo
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-02-13       Impact factor: 2.503

Review 5.  Involvement of level IIb lymph node metastasis and dissection in thyroid cancer.

Authors:  Yusuf Vayisoglu; Cengiz Ozcan
Journal:  Gland Surg       Date:  2013-11

6.  Status of level IIb lymph nodes of the neck in squamous cell carcinoma of the oral tongue in patients who underwent modified radical neck dissection and lymph node sentinel biopsy.

Authors:  M Manola; C Aversa; L Moscillo; S Villano; E Pavone; C Cavallo; A Mastella; F Ionna
Journal:  Acta Otorhinolaryngol Ital       Date:  2011-06       Impact factor: 2.124

7.  Effectiveness and pitfalls of elective neck dissection in N0 laryngeal cancer.

Authors:  A Deganello; G Gitti; G Meccariello; G Parrinello; G Mannelli; O Gallo
Journal:  Acta Otorhinolaryngol Ital       Date:  2011-08       Impact factor: 2.124

8.  Cervical metastasis on level IV in laryngeal cancer.

Authors:  V J Furtado de Araújo Neto; C R Cernea; R Aparecido Dedivitis; V J Furtado de Araújo Filho; J Fabiano Palazzo; L Garcia Brandão
Journal:  Acta Otorhinolaryngol Ital       Date:  2014-02       Impact factor: 2.124

9.  Current advances in diagnosis and surgical treatment of lymph node metastasis in head and neck cancer.

Authors:  A Teymoortash; J A Werner
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2012-12-20

10.  Rational surgical neck management in total laryngectomy for advanced stage laryngeal squamous cell carcinomas.

Authors:  Arne Böttcher; Christian S Betz; Stefan Bartels; Bjoern Schoennagel; Adrian Münscher; Lara Bußmann; Chia-Jung Busch; Steffen Knopke; Eric Bibiza; Nikolaus Möckelmann
Journal:  J Cancer Res Clin Oncol       Date:  2020-08-18       Impact factor: 4.553

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.